Generative AI in Beauty Device Manufacturing: The Emerging Technology Landscape

LinkedIn
페이스북
핀터레스트
레딧

목차

Conceptual beauty device alongside a CAD wireframe and abstract digital panel.
AI-generated concept illustration of hardware engineering and software integration, not an existing product.

Generative AI in Beauty Device Manufacturing: The Emerging Technology Landscape

Generative AI is becoming part of the beauty industry, but its role in beauty device manufacturing is more specific—and less mature—than the phrase “AI-powered beauty” suggests. The clearest commercial evidence sits in enterprise tools and digital skin experiences. Evidence of generative models designing production-ready beauty hardware, controlling factory processes, or autonomously selecting treatment energy remains limited.

For manufacturers and beauty brands, the emerging opportunity is to connect these capabilities to established engineering and product workflows. A language model can help retrieve technical knowledge. A generative design system can propose a candidate geometry. A skin-simulation platform can create an illustrative image. None of those outputs, by itself, establishes that a device is safe, effective, or ready for production.

The technology landscape is therefore not a single race to build an autonomous beauty instrument. It is a set of developing relationships between hardware manufacturers, beauty groups, AI software providers, and engineering platforms. Understanding those relationships is more useful than treating every smart device as a generative-AI breakthrough.

How Generative AI Fits Into the Beauty Device Value Chain

A connected beauty device may use several kinds of software without using generative AI at all. Computer vision can analyze an image. A recommendation system can select from approved options. Firmware can enforce operating limits. Generative AI adds a different capability: producing new text, imagery, or design candidates in response to inputs.

That distinction matters because the responsibilities are different. Explaining an instruction is not the same as measuring skin. Generating a product concept is not the same as validating its structure. Producing a plausible-looking result is not the same as proving a physical outcome.

The existing 가정용 미용 기기 기술 가이드 provides useful hardware context. An AI feature should be assessed alongside the device’s intended function and target-market requirements, rather than used to obscure them.

Engineering Knowledge and Development Assistance

One potential application is a controlled assistant that retrieves approved specifications, summarizes test records, or helps engineers prepare a design-change draft. Retrieval-augmented generation, or RAG, connects a language model to relevant documents before it answers.

McKinsey identifies internal search, task automation, and innovation support as beauty-industry opportunities. Its examples also describe using formulation data, process parameters, and prior research to assist product development. These support the direction of travel, but the analysis covers the broader beauty sector—not measured results from beauty-device factories.

For an OEM/ODM business, the proposed value is better access to existing knowledge. The limiting factor is whether that knowledge is authorized, current, and traceable. A model that retrieves an obsolete specification can make a familiar manufacturing problem harder to detect.

Generative CAD and Engineering Design

Generative design becomes relevant to manufacturing when it produces something engineers can edit and evaluate, not merely a product rendering.

Microsoft Research has demonstrated parametric CAD generation and natural-language editing through projects including FlexCAD, CADFusion, and CAD-Editor. Autodesk has also announced a direction toward neural CAD and generative foundation models for engineering tools.

Exploded concept beauty device beside a teal wireframe CAD model and prototype shells.
AI-generated concept illustration: design candidates still require engineering review and physical validation.

For beauty hardware, possible applications include exploring enclosure geometry, grip variations, and component layouts. The output still needs checks for tolerances, assembly, thermal behavior, and the integration of electronics and treatment components.

These are credible technical building blocks, not evidence that generative CAD is already standard practice in beauty-device production. They belong inside a design and engineering process that can reject unsuitable candidates.

Skin Simulation and Companion Software

Haut.AI’s SkinGPT is a clearer commercial generative-AI example. Microsoft’s customer case describes a commercial launch in January 2025 and a platform combining skin analysis with generated simulations.

Perfect Corp. illustrates the coexistence of different model types. NVIDIA’s technology case describes computer-vision skin analysis alongside diffusion-based digital beauty experiences. That establishes generative capability in software, not autonomous operation of a physical device.

Tablet displaying a stylized facial landmark model beside a conceptual handheld beauty device.
AI-generated concept illustration of companion software, not a diagnosis or a prediction of treatment results.

Such tools could be integrated into an app, consultation experience, or research workflow. But a generated skin image does not establish what a particular LED, RF, or microcurrent device will do to an individual user. A simulation should not be mistaken for clinical evidence or an unqualified promise of results.

Synthetic images may also support software development. Their usefulness must be tested on independent real-world data; realistic appearance alone does not demonstrate representative coverage or better model performance.

The Competitive Landscape Has Several Distinct Layers

The companies participating in this field do not all compete for the same role. Some own hardware platforms and customer relationships. Others provide models, digital experiences, or engineering infrastructure.

Consumer Beauty Device Brands

APR/Medicube and FOREO represent established consumer-device approaches. Medicube’s published Booster Pro X2 information includes an app and an AI Mode for personalized recommendations. FOREO’s portfolio spans cleansing and other beauty-device technologies.

Their public descriptions should not be read as proof of generative control. A feature called “AI Mode” may rely on analysis, recommendation, or rules without generating new treatment instructions.

For these brands, generative software could extend onboarding, support, or digital engagement. That is an opportunity assessment, not a claim that such integration has already been demonstrated in the products cited.

Professional Aesthetic Device Manufacturers

Lumenis and Candela occupy a different position, with professional energy-based equipment and associated clinical and service requirements. Their portfolios include technologies such as lasers, intense pulsed light, and radiofrequency.

Their presence matters because professional equipment cannot be evaluated by the same criteria as a cosmetic app. Engineering performance, intended use, operator requirements, and clinical evidence remain central. The public materials reviewed do not establish that generative AI controls their treatments or manufacturing processes.

Chinese OEM/ODM and Manufacturing Suppliers

The manufacturing layer contributes product engineering, component integration, testing, and production. Solex, for example, displayed AI-related skin-analysis and beauty devices in 2024 and described investments in testing, automation, and manufacturing execution systems.

This is evidence of intelligent hardware and digital manufacturing activity. It is not evidence that a generative model is selecting production parameters or releasing finished devices.

For an OEM/ODM supplier, the potential advantage is connecting software to a repeatable physical product. That requires clarity about who owns the data, who maintains the model, and who is responsible when a software update changes the product experience.

Beauty Groups, Software Providers, and Infrastructure Companies

L’Oréal operates across brand ownership, scientific research, digital services, and beauty technology. Haut.AI and Perfect Corp. provide software capabilities. Microsoft and NVIDIA provide AI infrastructure, while Autodesk and CAD research teams contribute engineering tools.

These roles can complement one another. A manufacturer need not build a foundation model to benefit from it. Conversely, access to a model does not confer manufacturing competence or regulatory approval.

The likely competitive issue is how effectively organizations combine domain knowledge with validated hardware and useful software—not which company uses the largest model.

What L’Oréal and P&G Show About Corporate Strategy

L’Oréal’s Perso combines skin analysis, environmental information, preferences, and personalized cosmetic dispensing. Its published description supports an AI-enabled personalization workflow, but does not establish that Perso uses generative AI.

The group’s clearly disclosed generative activity sits elsewhere: enterprise tools, content production, and research collaborations. Its IBM partnership concerns a foundation model for cosmetic formulation, which is relevant to beauty R&D but distinct from the structural design or energy control of an instrument.

Its transactions and partnerships also serve different purposes. L’Oréal acquired ModiFace in 2018, adding digital beauty capabilities. Cell BioPrint was announced through an exclusive technology partnership with NanoEnTek. The latter announcement does not establish an equity investment.

The strategic signal is capability integration. It is not evidence that every technology in the group’s portfolio has already been combined into a generative-AI device.

P&G’s Opté provides a historical hardware example. At launch, P&G Ventures described a system combining imaging, algorithms, and precision dispensing, developed through its internal startup studio. The description does not establish generative AI.

Its history also cautions against equating technical novelty with sustained commercial success. Industry reporting in 2023 described the business being wound down. Opté should therefore be discussed as a technology and commercialization case, not a currently expanding generative-device platform.

For future projects, the lesson is that a distinctive combination still needs a viable product experience and commercial proposition. Adding a language model does not remove those requirements.

Patents Reveal the Building Blocks—Not Automatic GenAI Adoption

Patents can help identify where companies have developed technical capabilities. They cannot, by themselves, establish deployment, product effectiveness, or the use of a particular AI architecture.

L’Oréal’s US10776800B2 describes skin-care composition personalization with skin information and a dispensing-related workflow. P&G’s US9949552B2 describes a handheld apparatus using image capture and a processor to identify skin deviations, with a nozzle delivering a treatment composition.

These records illustrate connections between sensing, information processing, and physical output. The disclosed descriptions do not justify relabeling them as generative-AI beauty-device patents.

Likewise, a patent that describes producing a formulation or recommendation is not necessarily using a generative model in the modern technical sense. Its actual disclosure and claims must be examined. A patent’s relationship to a named commercial product also needs separate evidence.

For manufacturers, this distinction prevents a misleading picture of the competitive landscape. Existing hardware and personalization IP may remain relevant to a new software-enabled concept, even if the original invention predates current generative models. Legal status, territorial scope, and freedom to operate require separate professional assessment.

Investment Signals Are Clearer in Software Than in GenAI Hardware

The available capital evidence is easier to interpret when software financing, hardware investment, and corporate partnerships are kept separate.

Haut.AI disclosed a €2 million external funding round in November 2023 for its skin-personalization software and generative-AI development. That is a financing amount for an adjacent software business—not a valuation or a beauty-device manufacturing investment.

Perfect Corp.’s 2024 Form 20-F describes generative-AI development and related investment needs. Its disclosed revenue and subscription activity belong to the company’s software business; they should not be presented as a standalone generative-AI hardware market.

L’Oréal’s BOLD fund made a minority investment in Debut in 2023. The announcement concerns biotechnology and biomanufacturing, rather than a demonstrated generative-AI beauty instrument. It is a useful example of corporate technology investment, but not evidence for the size of the device segment.

Together with the ModiFace acquisition and NanoEnTek partnership, these cases show several ways a beauty group can acquire capabilities. They do not form a comparable pool of generative-AI device transactions.

The current evidence does not support a reliable standalone market size or investment total for “generative AI in beauty device manufacturing.” Broad beauty-AI figures and consumer-device revenues cannot fill that gap without changing the meaning of the category.

Regulation Depends on the Device and the Function AI Performs

Generative AI does not create a separate exemption from product regulation. The relevant questions include what the device is intended to do, how it interacts with the body, and whether its software affects a safety-critical function.

China: Product Classification Still Comes First

China’s National Medical Products Administration specified an April 1, 2026 registration requirement for the RF treatment products covered by its 2024 announcement. The announcement must be read against the relevant product classification; it does not classify every cleansing, LED, or microcurrent product in the same way.

“Home use” is not, by itself, a reason to disregard the requirements applicable to a covered RF product. Equally, a broad statement that all beauty devices follow one medical-device route would be incorrect.

AI must then be assessed according to its role. Drafting an internal document is different from generating a recommendation that affects treatment settings. The consequences depend on the actual function, not the name given to the software.

United States: Intended Use and Controlled Software Changes

FDA’s aesthetic-device framework emphasizes intended use and product characteristics. Its 2025 RF microneedling safety communication identifies serious complications and states that RF microneedling is a medical procedure that should not be used at home. That communication is specific to the technology discussed, not a blanket ban on all home-use RF products.

For applicable AI-enabled device software, FDA’s final guidance on predetermined change control plans addresses planned modifications, validation methods, and impact assessment. It is not permission to make unrestricted model updates after launch.

For manufacturers, the implication is that software maintenance can become part of the regulated product lifecycle. A model replacement is not necessarily a purely commercial software decision.

European Union: Both Hardware and AI Rules May Matter

The EU Medical Device Regulation addresses device classification and conformity assessment. Importantly, it also covers specified groups of products without an intended medical purpose under Annex XVI. An aesthetic-only claim therefore does not automatically exempt every device from the MDR framework.

The AI Act adds another assessment where an AI system is a covered product or its safety component and the relevant conditions, including third-party conformity assessment, are met. Not every beauty chatbot or engineering assistant is consequently a high-risk AI system.

MDR requirements and AI Act obligations are distinct. A change to an AI implementation timetable should not be interpreted as removing a device’s existing conformity obligations. Product-specific assessment and current legal texts remain necessary.

Photos, Health Information, and Generated Claims

Skin imagery and personalization data also create responsibilities beyond device operation. China’s Personal Information Protection Law identifies biometric and medical-health information as sensitive personal information, with corresponding safeguards. The significance of a photograph depends on how it is processed and used.

Generated content introduces a separate evidence issue. L’Oréal’s published CreAItech principles state that it does not use realistic generated skin, hair, face, or body content to prove or enhance product benefits.

That is a corporate policy, not a universal regulatory rule. It nevertheless illustrates a practical distinction: an illustrative image should not be passed off as a real outcome. Device-specific claims still need appropriate substantiation.

Enterprise Adoption Is Advancing Faster Than Autonomous Device Operation

The most visible enterprise adoption pattern is a company-controlled workflow built on external technology. L’Oréal’s annual reporting describes broad employee use of generative AI; its CreAItech platform provides a concrete content-production example.

That supports the claim that adoption has moved beyond isolated demonstrations. It does not show that generative models are running beauty-device production lines or releasing products from quality control.

For manufacturers, three boundaries deserve attention. Technical records need version control. Customer and design data need appropriate access separation. Generated outputs need a defined approval route. These requirements become more important when an assistant is connected to engineering or quality systems rather than used for general writing.

Measurement quality is another constraint. A 2025 study comparing skin-tone assessment methods found limitations in photographic measurement and cautioned against using Fitzpatrick type as a substitute for skin tone. Better generated explanations cannot compensate for unstable or unsuitable input measurements.

NIST’s generative-AI risk profile treats evaluation and risk management as lifecycle activities. It is a voluntary framework, not a product authorization, but its emphasis is relevant to deployment that continues changing after launch.

Conceptual beauty device in a test fixture with bench instruments and a technician reviewing a tablet.
AI-generated concept illustration of human-reviewed testing, not a photograph of a specific manufacturing facility.

For physical products, these controls complement prototype verification and pilot production. They do not replace engineering tests or the evidence needed for product claims.

The Outlook: More Integrated Engineering, With a Higher Evidence Threshold

The nearer-term direction is likely to be integration: generative tools working with existing documents, CAD, analysis software, and validated hardware. The longer-term possibility is a more tightly connected system combining sensing, physical models, and constrained planning. These are analytical judgments, not guaranteed adoption schedules.

Multimodal skin models are relevant to that development, but a foundation model is not necessarily generative. PanDerm’s research demonstrates a multimodal vision foundation model for dermatology; it does not establish a validated model of an individual’s response to a beauty treatment.

Digital twins also require more than a realistic representation. A 2025 review of human digital twins found that only 18 of 149 included studies fully met its definition combining personalization, dynamic updating, and prediction. That is a research-maturity observation, not a beauty-device adoption rate.

A credible device-development application would connect a model to physical measurements and uncertainty assessment. A static face simulation or a generated before-and-after image should not be presented as an individual predictive twin without that evidence.

The developments that would materially change the landscape are therefore concrete: manufacturer-specific deployments, designs that survive production validation, performance evaluated across relevant users, and evidence from continued use. Model size, patent counts, and partnership announcements cannot substitute for those signals.

For OEM/ODM buyers, the practical distinction is between a feature that creates a useful, controlled output and one that merely creates an AI label. The former can become part of a sound product strategy; the latter adds complexity without demonstrating value.

Explore Nicemay’s home-use beauty device manufacturing options for the underlying hardware and development routes, or discuss a product development project. Any proposed generative-AI function should be scoped separately, with clear ownership of the software, data, validation, and ongoing maintenance.

참고 문헌

[1] L’Oréal Annual Report 2025: enterprise AI adoption and beauty technology

[2] Microsoft customer story: Haut.AI and SkinGPT commercial deployment

[3] Microsoft Research: parametric CAD generation and editing

[4] McKinsey: scaling generative AI across the beauty industry

[5] Autodesk: generative foundation models and neural CAD direction

[6] NVIDIA: Perfect Corp. computer vision and diffusion-based beauty experiences

[7] Medicube: Booster Pro X2 connected features and AI Mode

[8] FOREO: consumer beauty technology portfolio

[9] Lumenis: professional aesthetic energy-based devices

[10] Candela: aesthetic-device manufacturing and company profile

[11] Solex: AI-related beauty devices and digital manufacturing activity in 2024

[12] L’Oréal: Perso personalized cosmetic dispensing

[13] IBM and L’Oréal: foundation-model collaboration for cosmetic formulation

[14] L’Oréal: acquisition of ModiFace in 2018

[15] L’Oréal: Cell BioPrint and its NanoEnTek partnership

[16] P&G Ventures: Opté launch and internal venture development

[17] The Business of Fashion: P&G winds down Opté in 2023

[18] L’Oréal patent record: skin-care composition personalization and dispensing

[19] P&G patent record: handheld treatment apparatus with image analysis and dispensing

[20] BeautyMatter: Haut.AI funding round of €2 million in 2023

[21] Perfect Corp. 2024 Form 20-F: generative AI development and software business

[22] L’Oréal: BOLD minority investment in biotechnology company Debut

[23] NMPA announcement 84 of 2024: RF treatment product registration transition

[24] FDA: intended use and oversight of aesthetic devices

[25] FDA: RF microneedling safety communication dated October 15, 2025

[26] FDA: final guidance on predetermined change control plans for AI-enabled device software

[27] EU Medical Device Regulation: scope and products without an intended medical purpose

[28] EU AI Act consolidated text: product-related high-risk AI conditions

[29] China Personal Information Protection Law: sensitive personal information

[30] L’Oréal: CreAItech deployment and generated-content principles

[31] Study of skin-tone measurement, photographic limitations, and dataset labeling

[32] NIST: Generative Artificial Intelligence Risk Management Profile

[33] PanDerm: multimodal vision foundation model for clinical dermatology

[34] Scoping review of human digital twins in healthcare and research maturity

맨 위로 이동

저희에게 요청 사항을 제출해 주세요

12시간 이내에 답변해 주세요